ImmuneRegen BioSciences'(R) Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine
21 Dicembre 2009 - 2:00PM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced that
treatment with sar9, met(O2)11 Substance P, the active component of
Homspera®, revealed a positive adjuvant effect during a preventive
study for melanoma vaccine in mice. The positive results include
reduced tumor growth and improved mouse survival compared to
administration of vaccine alone. The latest findings seem to
indicate the adjuvant potential of Homspera, and extend to the
cancer vaccine space in addition to previously shown efficacy of
Homspera in infectious disease models such as influenza.
The study was performed at the University of Pittsburgh under
the guidance of Dr. Adriana Larregina, Associate Professor of
Dermatology and Immunology, at the University of Pittsburgh School
of Medicine using commercially available reagents from Bachem and
Sigma. These results encourage future experimentation for
therapeutic studies in mice. The demonstrated adjuvant effect,
including the reduction in tumor growth, as well as other
indicators of enhanced immune system activity against the vaccine's
antigen, suggest Homspera could be an effective adjuvant with
cancer vaccines. Since the completion of the studies Dr. Larregina
has joined ImmuneRegen's Scientific Advisory Board and Bachem has
agreed to provide GMP-grade Homspera (sarSP) to ImmuneRegen for
future studies.
ImmuneRegen's Chief Scientific Officer, Hal Siegel, Ph.D., noted
"We have previously shown a wide range of activity for Homspera,
from human hematopoietic stem cell activation and maturation, to
acceleration of wound healing, stand-alone treatment of pandemic
influenza infection and vaccine adjuvant activity. A common thread
in our studies is the stimulation of immune cell function. On
reviewing the published study results from Dr. Larregina's lab, as
well as other findings, we are enthused about the potential for
Homspera having a positive therapeutic effect in mice as well as in
future human trials, and the Company is now focused on aggressively
moving forward to complete the preclinical research needed to
prepare for human studies."
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera®. Homspera is an adult stem cell active
compound that in study results has been shown to regenerate and
strengthen the immune system and enhance wound healing. Homspera is
being developed for potential use against infectious diseases as a
stand-alone or combination therapy and as a vaccine adjuvant. To
advance its mission, the Scottsdale, Arizona based company has
forged numerous study partnerships with industry and academic
leaders, including Celgene Cellular Therapeutics, HemoGenix,
Lovelace Respiratory Research Institute and Virion Systems. For
more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential use and scientific results for
ImmuneRegen's drug candidates, science and technology, and all
other statements in this press release other than historical facts,
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. ImmuneRegen intends that
such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result
of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited
to the fact that future results or research and development efforts
may prove less encouraging than current results or cause side
effects not observed in current pre-clinical trials), the
evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic
report on Form 10-KSB for the year ended December 31, 2008 as filed
with the Securities and Exchange Commission. There are no
guarantees that any of ImmuneRegen's proposed products will prove
to be commercially successful. ImmuneRegen undertakes no duty to
update forward-looking statements.
Contact: Michael K. Wilhelm OR John Fermanis ImmuneRegen
BioSciences Inc. Phone: 480-922-3926 Email: Email Contact Email:
Email Contact
Grafico Azioni IR BioSciences (CE) (USOTC:IRBS)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni IR BioSciences (CE) (USOTC:IRBS)
Storico
Da Lug 2023 a Lug 2024